M. Delay

发表

Modulation of phenotypic expression of APOA5 Q97X and L242P mutations.

P. Moulin, A. Sassolas, M. Charcosset, 2009, Atherosclerosis.

Correction: Post-Heparin LPL Activity Measurement Using VLDL As a Substrate: A New Robust Method for Routine Assessment of Plasma Triglyceride Lipolysis Defects

M. Lagarde, P. Moulin, A. Sassolas, 2014, PloS one.

Post-Heparin LPL Activity Measurement Using VLDL As a Substrate: A New Robust Method for Routine Assessment of Plasma Triglyceride Lipolysis Defects

M. Lagarde, P. Moulin, A. Sassolas, 2014, PloS one.

GPIHBP1 C89F neomutation and hydrophobic C-terminal domain G175R mutation in two pedigrees with severe hyperchylomicronemia.

E. Lefai, P. Moulin, N. Peretti, 2011, The Journal of clinical endocrinology and metabolism.

Combination of circulating antilipoprotein lipase (Anti-LPL) antibody and heterozygous S172 fsX179 mutation of LPL gene leading to chronic hyperchylomicronemia.

B. Estour, M. Lagarde, P. Moulin, 2005, The Journal of clinical endocrinology and metabolism.

An APOA5 3' UTR variant associated with plasma triglycerides triggers APOA5 downregulation by creating a functional miR-485-5p binding site.

E. Lefai, S. Rome, P. Moulin, 2014, American journal of human genetics.

Multiple microRNA regulation of lipoprotein lipase gene abolished by 3'UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter.

M. Lagarde, J. Dallongeville, A. Meirhaeghe, 2016, Atherosclerosis.

Post-Heparin LPL Activity Measurement Using VLDL As a Substrate: A New Robust Method for Routine Assessment of Plasma Triglyceride Lipolysis Defects

M. Lagarde, P. Moulin, A. Sassolas, 2014, PloS one.

Correction: Post-Heparin LPL Activity Measurement Using VLDL As a Substrate: A New Robust Method for Routine Assessment of Plasma Triglyceride Lipolysis Defects

M. Lagarde, P. Moulin, A. Sassolas, 2014, PloS one.